Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Nature Reviews Drug Discovery Year : 2009

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

Abstract

NF-kB transcription factors have a key role in many physiological processes, such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-kB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-kB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-kB in cancer, and the possible complications and pitfalls of such an approach, are explored.
Fichier principal
Vignette du fichier
inserm-00352349_edited.pdf (1.49 Mo) Télécharger le fichier
FiguresVBaudrevised.ppt (311.5 Ko) Télécharger le fichier
V.Baudrevised2NRDD.pdf (289.69 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00352349 , version 1 (03-07-2009)

Identifiers

Cite

Véronique Baud, Michael Karin. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.. Nature Reviews Drug Discovery, 2009, 8 (1), pp.33-40. ⟨10.1038/nrd2781⟩. ⟨inserm-00352349⟩
313 View
1085 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More